4th edition Bioproduction of Immunotherapies

28 October 2019

 4th edition Bioproduction of Immunotherapies
September 24, 2019 at Biocitech, Romainville

The 4th edition of the Bioproduction of Immunotherapies co-organized by MabDesign and Medicen Paris Region took place at Biocitech on September 24th 2019.
This growing event gathered together more than 130 participants from over 90 companies to discuss and learn more about the latest innovations on the Immunotherapies Bioproduction.

This conference welcomed 16 high-profile speakers as Sanofi, LEEM, Pierre Fabre, Merck Serono, Regimbeau, Novartis, bioMérieux, XpressBiologics, Genomic Vision, Quality Assistance, Novasep, UCB, IMT, Roche. Moreover, the companies Anaquant, GTP Technology, KD BIO, MAbSilico, MImAbs, PathoQuest, SiaMed’Xpress & TreeFrog Therapeutics were selected to present their disruptive innovation during the Breakthrough Innovation Session.

The Program included the following sessions:
– How TPP/QTPP allows the optimization of immunotherapies development?
– USP optimization (Upstream Processing)
BREAKTHROUGH INNOVATION SESSION – Short presentations of innovative projects from both industries and academia
– DSP optimization (Downstream Processing)

The theme of this year edition was on « Immunotherapies: balancing Critical Quality Attributes and bioproduction yields » a major topic chosen by the Scientific Advisory Board.

The Exhibition Hall reunited  26 exhibitor companies showcasing their latest innovations: IMT, Genomic Vision, Regimbeau, Roche, Xpress Biologics, Agro-Bio, Anaquant, Andrew Alliance, Aseptic Technologies, Biotem, Chemometec, EFS, Indicia, Iprasense, KDBIO, Labtoo, Lymphobank, Myriade, PathoQuest, Perkin Elmer, Proteigene, RD-Biotech, tebu-bio, Texcell, ThermoFisher & Safas.

Moreover, +250 B2B meetings were held through an online platform allowing to meet new clients/ partners as set up new business opportunities.

Do not forget to add to your agenda:

Please contact us if you want more information.